In this retrospective observational study of nivolumab monotherapy in previously treated advanced non–small-cell lung cancer, overall survival (OS) in real-world patients with good performance status was similar to OS observed in pivotal clinical trials. Poor performance status and tumor programmed death ligand 1 expression < 1% were associated with shorter survival; advanced age had no significant adverse effect on survival.
Bibliographical noteFunding Information:
This study was supported by Bristol Myers Squibb . D.D.S. reports research funding to his institution from Bristol Myers Squibb , Novartis, AstraZeneca, and Bioverativ , and personal consulting fees from Salarius Pharmaceuticals, Iterion Therapeutics, Dracen Pharmaceuticals, Molecular Templates, and Bristol Myers Squibb. S.J.L., K.G.-S., Y.Z., T.K.L., and J.R.P. are employees and stockholders of Bristol Myers Squibb. C.B.S. reports speaker fees from Teva Pharmaceuticals.
Medical writing assistance was provided by Roland Tacke, PhD, Evidence Scientific Solutions, funded by Bristol Myers Squibb .
© 2020 The Authors
- Advanced age
- Observational study
- Overall survival
- Performance status
- Progression-free survival
PubMed: MeSH publication types
- Journal Article